Brief: Endo Announces Agreement With Slayback Pharma To Distribute Prevduo™
26/04/2023 12:31
April 26 (Reuters) - Endo International PLC ENDPQ.PK :
* ENDO ANNOUNCES AGREEMENT WITH SLAYBACK PHARMA TO
DISTRIBUTE
PREVDUO™ (NEOSTIGMINE METHYLSULFATE AND GLYCOPYRROLATE
INJECTION), THE FIRST AND ONLY FDA-APPROVED
NEOSTIGMINE-GLYCOPYRROLATE COMBINATION PRODUCT IN THE U.S.
* ENDO INTERNATIONAL PLC - WILL COMMERCIALIZE PREVDUO
THROUGH ITS
PAR STERILE PRODUCTS BUSINESS AND EXPECTS TO LAUNCH PRODUCT IN
JUNE 2023
Source text for Eikon: ID:nCNW6Y3BXa
Further company coverage: ENDPQ.PK
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes